{"id":"ad26-cov2-s-vaccine","safety":{"commonSideEffects":[{"rate":"48","effect":"Injection site pain"},{"rate":"35","effect":"Fatigue"},{"rate":"24","effect":"Headache"},{"rate":"23","effect":"Myalgia"},{"rate":"9","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-incompetent adenovirus serotype 26 (Ad26) as a vector to introduce genetic instructions for producing the SARS-CoV-2 spike protein. This triggers both cellular and humoral immune responses, enabling the body to recognize and neutralize the virus upon exposure. The single-dose formulation provides protection against COVID-19 infection and severe disease.","oneSentence":"Ad26.COV2.S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:42.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05220397","phase":"PHASE3","title":"Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Mark Stegall","startDate":"2022-04-11","conditions":"Kidney Transplant Recipient","enrollment":468},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT04765384","phase":"PHASE2","title":"A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-08-27","conditions":"COVID-19 Prevention","enrollment":51},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT05037266","phase":"PHASE4","title":"Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-09-20","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT05007080","phase":"PHASE2","title":"A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-09-27","conditions":"Coronavirus Disease-2019 (COVID-19) Prevention","enrollment":304},{"nctId":"NCT04614948","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-11-12","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19","enrollment":31835},{"nctId":"NCT04505722","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-09-07","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol","enrollment":44325},{"nctId":"NCT04436276","phase":"PHASE1, PHASE2","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-07-15","conditions":"Covid-19 Prevention","enrollment":1085},{"nctId":"NCT04999111","phase":"PHASE2","title":"A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-08-06","conditions":"Coronavirus Disease","enrollment":1541},{"nctId":"NCT04908722","phase":"PHASE3","title":"A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-06-18","conditions":"COVID-19 Prevention","enrollment":1609},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT05047640","phase":"PHASE3","title":"COVID-19 3rd Dose Vaccine in Transplant Patients","status":"TERMINATED","sponsor":"Giselle Guerra","startDate":"2021-09-14","conditions":"Covid19","enrollment":58},{"nctId":"NCT06360744","phase":"PHASE4","title":"A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.","status":"COMPLETED","sponsor":"Jens D Lundgren, MD","startDate":"2021-07-05","conditions":"SARS CoV 2 Infection","enrollment":25},{"nctId":"NCT05409261","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-06-02","conditions":"COVID-19, Vaccine Reaction, SARS CoV 2 Infection","enrollment":200},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05007860","phase":"","title":"Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-07-16","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT04535453","phase":"PHASE2","title":"A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-08-28","conditions":"Healthy","enrollment":635},{"nctId":"NCT04930055","phase":"","title":"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-06-30","conditions":"Cancer","enrollment":2206},{"nctId":"NCT05844202","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention","status":"COMPLETED","sponsor":"Alvea Holdings, LLC","startDate":"2022-06-27","conditions":"Sars-CoV-2 Infection","enrollment":130},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05081271","phase":"EARLY_PHASE1","title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","status":"TERMINATED","sponsor":"Griffin Hospital","startDate":"2021-10-15","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT05148845","phase":"PHASE3","title":"Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.","status":"UNKNOWN","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2021-11-10","conditions":"SARS CoV 2 Infection","enrollment":500000},{"nctId":"NCT04838795","phase":"PHASE3","title":"Sisonke (Together): OPEN LABEL TRIAL COVID-19","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2021-02-17","conditions":"SARS (Severe Acute Respiratory Syndrome)","enrollment":477102},{"nctId":"NCT05124483","phase":"PHASE2","title":"Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2022-04-21","conditions":"COVID-19","enrollment":600},{"nctId":"NCT05324319","phase":"PHASE2","title":"Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-06-15","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05030974","phase":"PHASE4","title":"RECOVAC Repeated Vaccination Study","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-10-21","conditions":"Covid19, Kidney Diseases, Vaccine Response Impaired","enrollment":336},{"nctId":"NCT05178264","phase":"","title":"Transverse Myelitis Related to SARS-CoV-2 Vaccines","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-12-10","conditions":"Vaccine Adverse Reaction","enrollment":580},{"nctId":"NCT04894305","phase":"PHASE1","title":"A Study of Ad26.COV2.S in Healthy Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-05-25","conditions":"Healthy","enrollment":380},{"nctId":"NCT04509947","phase":"PHASE1","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-08-11","conditions":"Healthy","enrollment":250},{"nctId":"NCT04817657","phase":"","title":"Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT04587219","phase":"PHASE2","title":"The Study of \"Gam-COVID-Vac\" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2020-10-22","conditions":"Coronavirus Infection","enrollment":110},{"nctId":"NCT04642339","phase":"PHASE3","title":"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2020-11","conditions":"Covid19","enrollment":2000},{"nctId":"NCT01375205","phase":"NA","title":"Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2011-06","conditions":"Atopic Dermatitis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":146,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ad26.COV2.S vaccine","genericName":"Ad26.COV2.S vaccine","companyName":"University Medical Center Groningen","companyId":"university-medical-center-groningen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ad26.COV2.S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19. Used for COVID-19 prevention in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}